Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G0TS
|
|||
| Former ID |
DCL000163
|
|||
| Drug Name |
Meclinertant
|
|||
| Synonyms |
Reminertant; SR 48692; SR48692; SR-48692; 2-(((1-(7-Chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)-1H-pyrazol-3-yl)carbonyl)amino)tricyclo(3.3.1.1(sup 3,7))decane-2-carboxylic acid; 2-((1-(7-Chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid;2-[[1-(7-chloroquinolin-4-yl)-5-(2,6-dimethoxyphenyl)pyrazole-3-carbonyl]amino]adamantane-2-carboxylic acid
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Inflammatory bowel disease [ICD-11: DD72; ICD-10: K50-K52] | Phase 2/3 | [1], [2] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Sanofi-aventis
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H31ClN4O5
|
|||
| Canonical SMILES |
COC1=C(C(=CC=C1)OC)C2=CC(=NN2C3=C4C=CC(=CC4=NC=C3)Cl)C(=O)NC5(C6CC7CC(C6)CC5C7)C(=O)O
|
|||
| InChI |
1S/C32H31ClN4O5/c1-41-27-4-3-5-28(42-2)29(27)26-16-24(36-37(26)25-8-9-34-23-15-21(33)6-7-22(23)25)30(38)35-32(31(39)40)19-11-17-10-18(13-19)14-20(32)12-17/h3-9,15-20H,10-14H2,1-2H3,(H,35,38)(H,39,40)
|
|||
| InChIKey |
DYLJVOXRWLXDIG-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 146362-70-1
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7980660, 10238378, 12014763, 14838157, 14862471, 29300128, 47359873, 48253930, 50068556, 52723268, 57339365, 85210068, 103593304, 104102755, 104407741, 113635342, 124950704, 127805129, 134223938, 134338840, 134345994, 135073852, 135651079, 136946549, 144240236, 152343782, 162011729, 162223896, 164045833, 164166845, 174527563, 177749793, 179149953, 198956518, 223704930, 227839908, 241376604, 249617961, 252157483, 252159918, 252216334, 252552607
|
|||
| ChEBI ID |
CHEBI:125516
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neurotensin receptor type 1 (NTSR1) | Target Info | Antagonist | [3], [4], [5] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Reactome | Peptide ligand-binding receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1582). | |||
| REF 2 | ClinicalTrials.gov (NCT00290953) Evaluation of the Overall Survival of Meclinertant Versus Placebo After a First Line Chemotherapy With Cisplatin + Etoposide. U.S. National Institutes of Health. | |||
| REF 3 | Neurotensin inversely modulates maternal aggression. Neuroscience. 2009 Feb 18;158(4):1215-23. | |||
| REF 4 | Stimulation by neurotensin of dopamine and 5-hydroxytryptamine (5-HT) release from rat prefrontal cortex: possible role of NTR1 receptors in neurop... Neurochem Int. 2008 Dec;53(6-8):355-61. | |||
| REF 5 | High-affinity neurotensin receptor is involved in phosphoinositide turnover increase by inhibition of sodium pump in neonatal rat brain. Neurochem Res. 2008 Nov;33(11):2206-13. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.